Erick Wayne DeVinney sold $171k of AXGN
Chief Innovation Officer at Axogen, Inc.. 5,221 shares at an average of $32.84, traded Mar 16, 2026, filed Mar 18, 2026.
Score components
- +15RoleOfficer
- +11Trade size$171k at market
- 0Share of holdings soldSold 1.9% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000805928-26-000048, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Common Stock | +6,363 | $0.00 | $0 | 259,297 | Mar 18, 2026 |
| Mar 16, 2026 | FTax withholding Common Stock | -2,870 | $32.84 | $94k | 256,427 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock | +11,575 | $0.00 | $0 | 268,002 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock | -5,221 | $32.84 | $171k | 262,781 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Restricted Stock Unitsderivative | +6,363 | $0.00 | $0 | 6,363 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Restricted Stock Unitsderivative | +11,575 | $0.00 | $0 | 11,575 | Mar 18, 2026 |
Related signals
Other insiders at Axogen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Axogen, Inc. | Joseph A. Tyndall director | $174k 3,500 shares | -25% | |
| 49Moderate | Axogen, Inc. | Lindsey Marie Hartley CFO | $442k 14,812 shares | -32% | |
| 60Notable | Axogen, Inc. | Kathy Johnson Weiler director | $1.4M 46,653 shares | -100% | |
| 50Moderate | Axogen, Inc. | Amy McBride Wendell director | $1.3M 43,684 shares | -32% | |
| 56Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $397k 13,222 shares | -42% | |
| 72Notable | Axogen, Inc. | Michael D Dale Chief Executive Officer | $750k 25,000 shares | -28% | |
| 49Moderate | Axogen, Inc. | Lindsey Marie Hartley CFO | $454k 14,387 shares | -31% | |
| 70Notable | Axogen, Inc. | Paul Thomas director | $634k 21,399 shares | -61% | |
| 49Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $290k 9,278 shares | -23% | |
| 48Moderate | Axogen, Inc. | Jens Kemp Chief Marketing Officer | $255k 8,156 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.